All In Biotech

Drug Trial Radar · NCT04924699

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Mar 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

350

Planned (sponsor's estimate)

Start

Jun 30, 2021

Primary completion

Sep 2023

Study completion Oct 2023

Sponsor

Lead sponsor
Shanghai Miracogen Inc.Industry
Sponsor type
Industry
First posted
Jun 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of Phase II is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive, unresectable locally advanced or metastatic breast cancer. The primary objective of Phase III is to evaluate the efficacy and safety of MRG002 versus Trastuzumab Emtansine (T-DM1) in patients with HER2-positive unresectable locally advanced or metastatic breast cancer who have been previously treated with trastuzumab (or a biosimilar) and an anti-HER2 tyrosine kinase inhibitor (anti-HER2-TKI) and have progressed on or after the most recent therapy.

Conditions

  • Advanced Breast Cancer
  • Metastatic Breast Cancer

Interventions

  • MRG002Drug

    Administrated intravenously

  • Trastuzumab Emtansine for InjectionDrug

    Administrated intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by Independent Review Committee (IRC)Time frame: Baseline to study completion(up to 36 months)

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Active not recruiting

  • Fifth Medical Center of PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China · Active not recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Active not recruiting

  • The Fourth hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Active not recruiting

  • The First Affiliated Hosipital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Active not recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Active not recruiting

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China · Active not recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Active not recruiting

  • Liaoning Cancer Hospital & Institute

    Shengyang, Liaoning, China · Active not recruiting

  • Jinan Central Hospital Affiliated to Shandong University

    Jinan, Shandong, China · Active not recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjing, Tianjing, China · Active not recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Active not recruiting

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Active not recruiting

  • Sir Run Run Shaw Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.